Presentation
Acute leukaemias (ALL and AML) are aggressive cancers whose prognosis varies depending on the underlying genetic abnormalities. STHD provides a comprehensive characterisation, in a single step, of genomic alterations in tumour cells and identifies potential molecular targets (theranostic markers) or deregulated biological pathways that are accessible to targeted therapies.
Criteria before considering a discussion in MDM-FMG
Patients ≥ 18 years of age diagnosed with acute myeloid or lymphoblastic leukaemia
AND
Tumour material available: blood or bone marrow with sufficient infiltration (or sorted tumour cells)
AND
Available non-tumoral material: remission sample (verified); or sorted lymphocytes/skin biopsy possible in the absence of remission
AND
Patient eligible for active treatment
Genome Sequencing in diagnostic strategy
MDM cartography
MDM-FMG National Adult Oncology and Haematology
SeqOIA
Emmanuelle CLAPPIER
Nicolas DUPLOYEZ
Raphaël ITZYKSON
Nicolas BOISSEL
AURAGEN
Pascale FLANDRIN
pascale.flandrin-gresta@chu-st-etienne.fr
Sylvie TONDEUR
Sophie PARK
Romain GUIEZE